Noema Pharma’s CHF 130m financing round: the advisors

Homburger advised Noema Pharma, a clinical-stage biotech company, on its successful closing of a Series B extension financing round with an investment from EQT Life Sciences, and with continued support from Jeito and Forbion, all advised by BGPartner. This brings the total capital raised in the round to CHF 130 million. With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises.

The financing will support Noema Pharma Ltd to advance four active Phase 2 trials targeting severe pain in trigeminal neuralgia and seizures in tuberous sclerosis complex, Tourette syndrome and childhood-onset fluency disorder. 

The teams

Homburger advised Noema Pharma as transaction counsel in this Series B extension financing round. The Homburger team comprised partner Andreas Müller, associate Thierry Burckhardt, associate Thomas Romelli, and junior associate Rebecca Sigrist (all corporate/M&A; healthcare/life sciences), partner Luca Dal Molin (IP/IT; healthcare/life sciences) as well as partner Stefan Oesterhelt and associate Laetitia Fracheboud (tax).

BGPartner advised EQT, Forbion and Jeito on all Swiss legal matters and the negotiations of this Series B extension and the initial Series B round. The team consisted of Oliver Gnehm (partner-pictured), Victoria Marty (senior associate) and Tessa Douma (associate).

Pictured from left to right: Andreas Müller, Luca Dal Molin, Stefan Oesterhelt

paolo.cannazza@lcpublishinggroup.com

SHARE